All In Biotech

Drug Trial Radar · NCT05074134

Absorption, Metabolism, and Excretion Study of [14C]-TNP-2092

An Open Label Phase 1 Study in Healthy Adult Male Subjects to Investigate the Absorption, Metabolism, and Excretion of [14C]-TNP-2092 Following a Single Intravenous Dose Administration

Last checked: Nov 20, 2026Latest source record: Oct 19, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

6

Actual

Start

Oct 16, 2021

Primary completion

Nov 30, 2021

Study completion Jul 12, 2022

Sponsor

Lead sponsor
TenNor Therapeutics LimitedIndustry
Sponsor type
Industry
First posted
Oct 12, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is an open-label, single dose, Phase 1 study conducted at a single study center in the United States (USA). This study will evaluate the absorption, metabolism and elimination (AME), mass balance, safety and tolerability of a single dose of intravenously administered \[14C\]-TNP-2092. Healthy men aged 18 to 55, will be screened, and subjects who meet all eligibility criteria and provide written informed consent will be enrolled into the study within 28 days of Screening. Subjects will be admitted to the clinical unit on the day prior to dosing (Day -1). Subjects will fast overnight and then given a standard breakfast 30 min prior to dosing. Six subjects will be enrolled in the study and each will receive a single intravenous (IV) dose of 300 mg/3 μCi \[14C\]-TNP-2092 administered over 60 minutes (±10 minutes).

Conditions

  • Healthy

Interventions

  • [14C]-TNP-2092Drug

    Subjects will receive a single intravenous (IV) dose of 300 mg/3 µCi \[14C\]-TNP-2092 administered over 60 minutes (± 10 minutes).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mass balance of TNP-2092 and the percentages of radiolabel recovered in urine and fecesTime frame: Day 7
  2. Pharmacokinetics (PK) of TNP-2092 in plasmaTime frame: Day 7
  3. Pharmacokinetics (PK) of TNP-2092 in plasmaTime frame: Day 7

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Pharmaron Clinical Pharmacology Center

    Baltimore, Maryland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.